文献速递心境障碍精神分裂症与精神病性障碍

精神分裂症多基因评分与双相障碍锂盐治疗反应的关联:全基因组关联研究

Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study.
PubMed 文献 · JAMA Psychiatry · 2018-01-01

该研究纳入2586例接受锂盐治疗的双相障碍患者,计算精神分裂症多基因评分并评估长期治疗反应。结果显示精神分裂症多基因负荷越高,锂盐治疗反应越差,交叉性状荟萃分析提示HLA抗原复合物和炎症细胞因子可能参与其中。

要点

  • 精神分裂症多基因评分与双相障碍锂盐治疗反应呈负相关。
  • 低精神分裂症多基因负荷患者锂盐治疗反应优于第10十分位患者。
  • 交叉性状荟萃分析识别15个可能重叠效应的遗传位点,涉及HLA抗原复合物和炎症细胞因子。

核心结论

  • 高精神分裂症遗传负荷与双相障碍患者锂盐治疗反应差存在负相关。

研究设计与样本

  • 研究纳入2586例接受锂盐治疗的双相障碍患者,于2008至2013年间进行基因分型和长期治疗反应评估。
  • 进行交叉性状荟萃全基因组关联研究和通路分析,结合精神分裂症与锂盐治疗反应的全基因组关联研究汇总统计量。

主要发现

  • 在分类结局中,精神分裂症多基因评分与锂盐治疗反应呈负相关,阈值P < 5 × 10⁻²。
  • 与精神分裂症风险第10十分位患者相比,第1十分位患者锂盐治疗反应的比值比为3.46(95% CI, 1.42-8.41),第9十分位为2.03(95% CI, 0.86-4.81)。
  • 交叉性状荟萃全基因组关联研究识别出15个可能对锂盐治疗反应和精神分裂症易感性有重叠效应的遗传位点。
  • 这些位点的功能通路和网络分析指向HLA抗原复合物和炎症细胞因子。

关键数值与推荐

  • 锂盐治疗反应采用双相障碍研究受试者长期治疗反应回顾性标准(Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder score)在分类和连续量表上定义。
  • 效应量包括比值比和解释方差比例。
  • 精神分裂症多基因评分在阈值P < 5 × 10⁻²时与锂盐治疗反应分类结局呈负相关。

临床怎么用

  • 精神分裂症多基因评分可能作为双相障碍患者锂盐治疗反应的潜在生物标记物。
  • 研究结果提示针对锂盐个体化处方的转化研究潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Lithium is a first-line mood stabilizer for the treatment of bipolar affective disorder (BPAD). However, the efficacy of lithium varies widely, with a nonresponse rate of up to 30%. Biological response markers are lacking. Genetic factors are thought to mediate treatment response to lithium, and there is a previously reported genetic overlap between BPAD and schizophrenia (SCZ). OBJECTIVES: To test whether a polygenic score for SCZ is associated with treatment response to lithium in BPAD and to explore the potential molecular underpinnings of this association. DESIGN, SETTING, AND PARTICIPANTS: A total of 2586 patients with BPAD who had undergone lithium treatment were genotyped and assessed for long-term response to treatment between 2008 and 2013. Weighted SCZ polygenic scores were computed at different P value thresholds using summary statistics from an international multicenter genome-wide association study (GWAS) of 36 989 individuals with SCZ and genotype data from patients with BPAD from the Consortium on Lithium Genetics. For functional exploration, a cross-trait meta-GWAS and pathway analysis was performed, combining GWAS summary statistics on SCZ and response to treatment with lithium. Data analysis was performed from September 2016 to February 2017. MAIN OUTCOMES AND MEASURES: Treatment response to lithium was defined on both the categorical and continuous scales using the Retrospective Criteria of Long-Term Treatment Response in Research Subjects with Bipolar Disorder score. The effect measures include odds ratios and the proportion of variance explained. RESULTS: Of the 2586 patients in the study (mean [SD] age, 47.2 [13.9] years), 1478 were women and 1108 were men. The polygenic score for SCZ was inversely associated with lithium treatment response in the categorical outcome, at a threshold P < 5 × 10-2. Patients with BPAD who had a low polygenic load for SCZ responded better to lithium, with odds ratios for lithium response ranging from 3.46 (95% CI, 1.42-8.41) at the first decile to 2.03 (95% CI, 0.86-4.81) at the ninth decile, compared with the patients in the 10th decile of SCZ risk. In the cross-trait meta-GWAS, 15 genetic loci that may have overlapping effects on lithium treatment response and susceptibility to SCZ were identified. Functional pathway and network analysis of these loci point to the HLA antigen complex and inflammatory cytokines. CONCLUSIONS AND RELEVANCE: This study provides evidence for a negative association between high genetic loading for SCZ and poor response to lithium in patients with BPAD. These results suggest the potential for translational research aimed at personalized prescribing of lithium.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Amare AT, Schubert KO, Hou L, et al. Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. JAMA Psychiatry. 2018. PMID: 29121268. doi:10.1001/jamapsychiatry.2017.3433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。